AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients
Language English Country Netherlands Media print-electronic
Document type Journal Article
PubMed
28238761
DOI
10.1016/j.yexmp.2017.02.016
PII: S0014-4800(16)30276-3
Knihovny.cz E-resources
- Keywords
- AGR2, Breast cancer, HER2,
- MeSH
- Humans MeSH
- RNA, Messenger genetics metabolism MeSH
- Mucoproteins MeSH
- Cell Line, Tumor MeSH
- Breast Neoplasms diagnosis genetics MeSH
- Oncogene Proteins MeSH
- Prognosis MeSH
- Cell Proliferation MeSH
- Proteins genetics metabolism MeSH
- Receptor, ErbB-2 genetics MeSH
- Receptors, Estrogen genetics MeSH
- Gene Expression Regulation, Neoplastic * MeSH
- Up-Regulation MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- AGR2 protein, human MeSH Browser
- ERBB2 protein, human MeSH Browser
- RNA, Messenger MeSH
- Mucoproteins MeSH
- Oncogene Proteins MeSH
- Proteins MeSH
- Receptor, ErbB-2 MeSH
- Receptors, Estrogen MeSH
Expression of the AGR2 oncogene was shown to be associated with estrogen receptor positive tumors. This gene contributes to enhanced cellular proliferation, drug resistance, metastasis development and may also serve as a predictor of poor prognosis. However, our analysis of AGR2 expression in a subset of estrogen-receptor negative tumors revealed that AGR2 could also be upregulated in hormone-independent manner. AGR2 expression was shown to be significantly increased in HER2 positive breast tumors on both the mRNA and the protein level. Moreover, in a subset of estrogen- and progesterone-receptor negative and simultaneously HER2-positive cases, increased AGR2 expression significantly correlated with worse patient prognosis. Subsequent analysis of independent data sets either collected in our institute or obtained from Oncomine cancer microarray database confirmed all these findings.
References provided by Crossref.org
